Is type 2 diabetes a different disease in obese and nonobese patients?

Diabetes Care

Volumn 21, Issue 10, 1998, Pages 1680-1685

  Prando, Romano ^a   Cheli, Valeria ^a   Melga, Pierluigi ^a   Giusti, Roberta ^a   Ciuchi, Emanuela ^a   Odetti, Patrizio ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CELL FUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; OBESITY; POSTPRANDIAL PERIOD;

EID: 0031681193     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.10.1680     Document Type: Article

References (57)

1. DeFronzo RA: Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia 15:389-397, 1992
2. Taylor SI, Accili D, Imai Y: Insulin resistance or insulin deficiency: which is the primary cause of NIDDM? Diabetes 43:735-739, 1994
3. Rossetti L, Giaccari A, DeFronzo RA: Glucose toxicity: the amplification of hyperglycemia in the pathophysiology of diabetes mellitus. Clin Invest Med 18:255-260, 1995
4. Robertson RP, Olson LK, Zhang HJ: Differentiating glucose toxicity from glucose desensitization: a new message from the insulin gene. Diabetes 43:1085-1089, 1994
5. Krall LP, Bradley RF: "Secondary failure" in the treatment of diabetes mellitus with tolbutamide and with phenformine. Diabetes 11:88-91, 1962
6. Groop L, Pelkonen R: Treatment failures: a common problem in the management of patients with type II diabetes. Acta Endocrinol 105 (Suppl. 262):131-135, 1984
7. Groop L, Schalin C, Franssila-Kallunki A, Widen E, Ekstrand A, Eriksson J: Characteristics of non-insulin dependent diabetic patients with secondary failure to oral antidiabetic therapy. Am J Med 87:187-190, 1989
8. Pontiroli AE, Calderara A, Pozza G: Secondary failure of oral hypoglycaemic agents: frequency, possible causes and management. Diabetes Metab Rev 10:31-43, 1994
9. Karan JH: Reversible insulin resistance in non-insulin-dependent diabetes mellitus. Horm Metab Res 28:440-444, 1996
10. Bottazzo GF: Beta-cell damage in diabetic insulitis: are we approaching a solution? Diabetologia 26:241-249, 1984
11. Gutniak M, Karlander S, Efendic S: Glyburide decreases insulin requirement, increases beta-cell response to mixed meal, and does not affect insulin sensitivity: effects of short- and long-term combined treatment in secondary failure to sulfonylurea. Diabetes Care 10:545-554, 1987
12. Genuth S: Insulin use in NIDDM. Diabetes Care 13:1240-1264, 1990
13. Kishikawa H, Hashimoto Y, Hashiguchi Y, Sazahara T, Nishiyama T, Yano T, Yamaguchi K, Shichiri M: Insulin treatment regimes for type II (non-insulin dependent) diabetes mellitus as judged by residual B-cell function. Diab Nutr Metab 4:305-312, 1991
14. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 20 (Suppl. 1):S5-S13, 1997
15. Pontiroli AE, Calderara A, Maffi P, Bonisolli L, Carenini A, Piatti PM, Monti LD. Gallus G, Pozza G, Illeni MT: Secondary failure to oral hypoglycemic agents in non obese patients with non insulin dependent diabetes is related to reduced insulin release. Diabéte Metab 15:79-84, 1989
16. Lyons TI, Kennedy L, Atkinson AB, Buchanan KD, Hadden DR, Weaver JA: Predicting the need for insulin therapy in late onset (40-69 years) diabetes mellitus. Diabet Med 1:105-107, 1984
17. Arner P, Pollare T, Lithell H: Different aetiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects. Diflbetotologia 34:483-487, 1991
18. Banerji MA, Lebovitz HE: Insulin action in black Americans with NIDDM. Diabetes Care 15:1295-1302, 1992
19. Bray GA: Overweight is risking fate: definition, classification, prevalence and risks. Ann N Y Acad Sci 499:14-28, 1987
20. Herbert V, Lav K, Gottlieb G, Bleicher S: Coated charcoal assay of insulin. J Clin Endocrinol Metab 25:1375-1379: 1965
21. Kaneto T, Oka H, Manemura M: Radioimmunoassay of human proinsulin and C-peptide using synthetic human connecting peptide. Endocrinol Japan 21:141-150, 1974
22. Prando R, Odetti P, Melga PL, Giusti G, Ciuchi L, Cheli V: Progressive deterioration of beta-cell function in non-obese type 2 diabetic subjects, Diabète Metab 22:185-191, 1996
23. Groop LC, Pelkonen R, Koskimies S, Bottazzo GF, Doniach D: Secondary failure to treatment with oral antidiabetic agents in non-insulin dependent diabetes. Diabetes Care 9:129-133, 1986
24. Snehalatha C, Ramachandran A, Mohan V, Timothy H, Viswanathan M: Beta-cell function in long term NIDDM (type 2) patients and its relation to treatment. Horm Metab Res 18:391-394, 1986
25. Clauson P, Linnarsson R, Gottsäter A, Sundkvist G, Grill V: Relationships between diabetes duration, metabolic control and βcell function in a representative population of type 2 diabetic patients in Sweden. Diabet Med 11:791-801, 1994
26. Seltzer HS, Harris VL: Exhaustion of insulinogenic reserve in maturity-onset diabetic patients during prolonged and continuous hyperglycemic stress. Diabetes 13:6-13, 1961
27. Madsbad S, Faber OK, Binder C, McNair P, Christensen C, Transbol I: Prevalence of residual beta-cell function in insulindependent diabetics in relation to age at onset and duration of diabetes. Diabetes 27 (Suppl. l):262-263, 1978
28. Cignarelli M, Cospite MR, Stefanelli G, Guastamacchia E, Mardelli G, Girgino R: Duration of residual beta-cell function in maturity onset diabetes. Acta Diabetol lot 21:161-166, 1984
29. Trischitta V, Italia S, Mazzarino S, Frittita L, Favetta A, Vigneri R: Non-insulin dependent diabetic patients have a progressively reduced insulin secretion in relation to the increased disease duration. Diab Nutr Metab 4:107-111, 1991
30. Hsieh SD, AkahumaY, Kawazu S, Mashiko S, Kanrawa Y. Iwamoto Y, Kikuchi M: Reduction of C-peptide secretion in non insulin dependent diabetic patients with long duration of insulin treatment. Endocrinol Japan 30:373-380, 1983
31. Kosada K, Akanuma Y: Heterogeneity of plasma IRI responses in patients with IGT. Diabetologia 18:347-348, 1980
32. Lev-Ran A, Hwang D, Barseghian G, Hill LR: Control of non insulin dependent diabetes is not correlated with endogenous insulin secretion. Diabète Metab 12:325-328, 1986
33. Lohmann D, Verlohren H-J: IRI-secretion in MOD with and without sulfonylurea (5 year control). Horm Metab Res 12:702-703, 1980
34. Hockaday DR, Pierlussi R, Dhar H: Maturity-onset type diabetics show no consistent pattern of deterioration in insulin secretion over five years of diagnosis, Diabetologia 19:283-288, 1980
35. Groop L, Tolppanen EM: Factors influencing beta-cell function and insulin sensitivity in patients with type 2 (non insulin-dependent) diabetes. Acta Endocrinol 106:505-510, 1984
36. LeahyJL: Natural history of B-cell dysfunction in NIDDM. Diabetes Care 13:992-1010, 1990
37. Porte D Jr: Banting Lecture 1990: β-cells in type II diabetes mellitus. Diabetes 40:166-180, 1991
38. Castillo MJ, Scheen AJ, Lefebvre PJ: Modified glucagon test allowing simultaneous estimation of insulin secretion and insulin sensitivity: application to obesity, insulindependent diabetes mellitus, and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 80:393-399, 1995
39. Olefsky JM, Kolterman OG: Mechanisms of insulin resistance in obesity and noninsulin-dependent type II diabetes mellitus. Am J Med 70:151-168, 1981
40. Pontiroli AE, Calderara A, Pacchioni M, Cassisa C, Pozza G: Weight loss reverses secondary failure of oral hypoglycaemic agents in obese non-insulin-dependent diabetic patients independently of the duration of the disease. Diabète Metab 19:30-35, 1993
41. Kelley DE, Wing R, Buonocore C, Sturis J, Polonsky K, Fitzsimmons M: Relative effect of caloric restriction and weight loss in non-insulin-dependent diabetes mellitus J Clin Endocrinol Metab 77:1287-1293, 1993
42. Wing RR, Blair EH, Bononi P, Marcus MD, Watanabe R, Bergman RN: Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients, Diabetes Care 17:30-36, 1994
43. Perriello G, Misericordia P, Volpi E, Pampanelli S, Santeusanio T- Brunetti P, Bolli GB: Contribution of obesity to insulin resistance in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 80:2464-2469, 1995
44. Hollenbeck CB, Chen Y-DI, Reaven GM: A comparison of the relative effects of obesity and non-insulin-dependent diabetes mellitus on in vivo insulin-stimulated glucose utilization. Diabetes 33:622-626, 1984
45. Firth R, Bell P, Rizza R: Insulin action in non-insulin-dependent diabetes mellitus: the relationship between hepatic and extrahepatic insulin resistance and obesity. Metab Clin Exp 36:1091-1095, 1987
46. Campbell PJ, Carlson MG: Impact of obesity on insulin action in NIDDM. Diabetes 42:405-410, 1993
47. Ludvik B, Nolan JJ, Baloga J, Sacks D, Olefsky J: Effect of obesity on insulin resistance in normal subjects and patients with NIDDM. Diabetes 44:1121-1124, 1995
48. DeFronzo RA, Bonnadonna RC, Ferrannini E: Pathogenesis of NIDDM: a precarious balance between insulin action and insulin secretion, In Inter-national Textbook of Diabetes Mellitus. 1st ed. Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, Eds. Chichester, U.K., John Wiley, 1992, p. 569-633
49. Polonsky KS, Gumbiner B, Ostrega D, Griver K, Tager H, Henry RR: Alterations in immunoreactive proinsulin and insulin clearance induced by weight loss in NIDDM. Diabetes 43:871-877, 1994
50. Faber OK, Christensen K, Kehlet H, Madsbad S, Binder C: Decreased insulin removal contributes to hyperinsulinemia in obesity J Clin Endocrinol Metab 53:618-621, 1981
51. Waldhausl WK, Bratusch-Marrain P, Gasic S, Korn A, Nowotny P: Insulin production rate, hepatic insulin retention and splanchnic carbohydrate metabolism after oral glucose ingestion in hyperinsulinemic type II diabetes mellitus. Diabetologia 23:6-15, 1982
52. Polonsky KS, Rubenstein AH: C-peptide as a measure of the secretion and hepatic extraction of insulin. Diabetes 33:286-294, 1984
53. Borissova AM, Koev DG, Minev MG, Martinova FG, Gencova PI, Kirilov GG, Arnaudov J: Factors for development of secondary failure to sulfonylurea drugs in non-insulin-dependent diabetes mellitus. Acta Diabetol Lat 28:91-98, 1991
54. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D: Diminished beta-cell secretory capacity in patients with non insulin dependent diabetes mellitus. J Clin Invest 74:1318-1328, 1984
55. Pfeiffer MA, Halter JD, Porte D Jr: Insulin secretion in diabetes mellitus. Am J Med 70:579-588, 1985
56. Laakso M, Ronnemaa T, Sarlund H, Pyorala K, Kallio V: Factors associated with fasting and postglucagon plasma C-peptide levels in middle-aged insulin-treated diabetic patients.. Diabetes Care 12:83-88, 1989
57. Nagulesparan M, Savage PJ, Bennion LJ, Unger RH, Bennet PH: Diminished effect of caloric restriction on control of hyperglycemia with increasing known duration of type II diabetes mellitus, J Clin Endocrinol Metab 53:560-568, 1981